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ABSTRACT
Background. Retrospective studies suggest that tacrolimus-
induced hypomagnesaemia is a risk factor for post-transplant
diabetes mellitus (PTDM), but prospective studies are lacking.
Methods. This was a prospective study with measurements of
serum magnesium and tacrolimus at pre-specified time points
in the first year after living donor kidney transplantation (KT).
The role of single nucleotide polymorphisms (SNPs) in hepato-
cyte nuclear factor 1b (HNF1b) was also explored because
HNF1b regulates insulin secretion and renal magnesium han-
dling. Repeated measurement and regression analyses were
used to analyse associations with PTDM.
Results. In our cohort, 29 out of 167 kidney transplant recipi-
ents developed PTDM after 1 year (17%). Higher tacrolimus
concentrations were significantly associated with lower serum
magnesium and increased risk of hypomagnesaemia. Patients
who developed PTDM had a significantly lower serum magne-
sium trajectory than patients who did not develop PTDM. In
multivariate analysis, lower serum magnesium, age and body
mass index were independent risk factors for PTDM. In recipi-
ents, the HNF1b SNP rs752010 G>A significantly increased
the risk of PTDM [odds ratio (OR) ¼ 2.56, 95% confidence in-
terval (CI) 1.05–6.23] but not of hypomagnesaemia. This associ-
ation lost significance after correction for age and sex (OR ¼
2.24, 95% CI 0.90–5.57). No association between HNF1b SNPs
and PTDMwas found in corresponding donors.
Conclusions. A lower serum magnesium in the first year after
KT is an independent risk factor for PTDM. The HNF1b SNP
rs752010 G>A may add to this risk through an effect on insu-
lin secretion rather than hypomagnesaemia, but its role requires
further confirmation.
Keywords: calcineurin inhibitors, hypomagnesaemia, post-
transplant diabetes mellitus, single nucleotide polymorphism,
tacrolimus
INTRODUCTION
Post-transplant diabetes mellitus (PTDM) is one of the major
metabolic complications after kidney transplantation (KT) [1–
5]. Kidney transplant recipients (KTRs) with PTDM have a re-
duced long-term graft function [6] and a higher risk of graft
failure [6–10], cardiovascular disease [5, 11, 12] and mortality
[5, 8–11, 13]. Of the identified risk factors of PTDM, hypomag-
nesaemia is of special interest, because it is potentially modifi-
able, and because a link between magnesium and diabetes
mellitus is becoming increasingly evident [14]. Magnesium acts
as an intracellular cofactor for several metabolic pathways, in-
cluding glucose transport and uptake, and insulin sensitivity
and secretion [15–21]. In non-transplant populations, lower se-
rum magnesium levels have been firmly linked to a higher risk
of diabetes mellitus, although it is unclear if this association is
causal [22, 23]. Hypomagnesaemia has also become a common
finding in KTRs after the introduction of calcineurin inhibitors
(CNIs) [24, 25]. CNIs down-regulate the transient receptor po-
tential melastatin 6, a magnesium channel in the distal convo-
luted tubule involved in the reabsorption of magnesium [26].
Thus, CNIs cause hypomagnesaemia through renal magnesium
loss [25]. CNIs are also a risk factor for PTDM and this risk
may be mediated through the effects of CNIs on magnesium
[2]. Indeed, in several retrospective studies, CNI-induced hypo-
magnesaemia has been associated with a higher risk of PTDM
[2, 27, 28], although this has not been a consistent finding [3,
29, 30]. Therefore, the main aim of this prospective study was
to analyse the roles of tacrolimus and serum magnesium on the
risk of developing PTDM.
The second aim of this study was to explore the potential
role of the transcription factor hepatocyte nuclear factor 1b
(HNF1b) in PTDM. HNF1b plays a role in both insulin secre-
tion and renal magnesium reabsorption [31]. Patients with
mutations in the HNF1b gene develop diabetes mellitus and
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hypomagnesaemia [31, 32], and single nucleotide polymor-
phisms (SNPs) in HNF1b are associated with diabetes mellitus
in the general population [33–36]. Interestingly, a recent study
showed that CNIs down-regulate HNF1b, increasing the risk of
PTDM 2- to 3-fold in patients with HNF1b mutations [37].
This provided a rationale to explore the role of HNF1b in KTRs
receiving tacrolimus.
MATERIALS AND METHODS
Study design and population
This study was embedded within an investigator-initiated,
prospective, randomized-controlled, parallel group, open-label,
single centre clinical trial [38]. The objective of this randomized
controlled trial was to investigate whether adaptation of the
tacrolimus starting dose according to CYP3A5 genotype instead
of body weight leads to an earlier achievement of the tacrolimus
target whole-blood exposure. The design and rationale of the
study have been described in detail elsewhere [38]. In brief, be-
tween 2010 and 2013, patients aged18 years who were sched-
uled to receive a single-organ, blood group AB0-compatible
kidney from a living donor in our centre, were screened. The fi-
nal study population consisted of 237 patients. All patients gave
written informed consent before inclusion and randomization.
The study pre-specified three whole-blood tacrolimus target
ranges: 10.0–15.0 ng/mL in Weeks 1 and 2; 8.0–12.0 ng/mL in
Weeks 3 and 4; and 5.0–10.0 ng/mL after Week 4 post-KTR.
The study was approved by the institutional review board of
the Erasmus MC (Medical Ethical Review Board number
2010-080) and was registered in the Dutch national trial
registry (http://www.trialregister.nl/trialreg/index.asp; number
NTR2226, registered 25 February 2010).
Measurements
Pre-specified measurements of serum and urine magnesium,
creatinine and non-fasting blood glucose levels were performed
prior to transplantation and at 7 days and 1, 3, 6 and 12 months
after KT. Blood and urine were collected on the same day.
Prior to KT, only blood was collected. The measurements
were performed by the Department of Clinical Chemistry
using the Cobas 8000 modular analyzer series (Roche).
Hypomagnesaemia was defined as serum magnesium level
<0.70 mmol/L. The estimated glomerular filtration rate (eGFR)
was calculated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation [39]. Urine magnesium was
expressed as ratio with urine creatinine. Whole-blood tacroli-
mus concentration was measured prospectively at 1, 3, 6 and
12 months after KT using an immunoassay. Because outpatient
visits were not always scheduled exactly at these time-points,
we allowed the following time windows for the measurements:
Month 1 (20–40 days), Month 3 (76–106 days), Month 6 (157–
207 days) and Month 12 (325–405 days). When multiple sam-
ples were available within the interval, the measurement closest
to the defined time point was used for analysis. Information on
age, sex, body mass index (BMI) and primary kidney disease of
the patients was derived from the electronic case report forms
of the original study.
Genetic analysis
To study the role of HNF1b in the risk of developing
PTDM, we used a candidate gene approach to select different
SNPs in HNF1b with a known association to diabetes mellitus
(rs752010 G > A, rs4430796 A > G and rs7501939 C > T)
[33]. To do so, DNAwas extracted from peripheral blood leuco-
cytes using the Blood DNA kit (Qiagen, Courtaboeuf, France)
in accordance with standard protocols. Genotyping of the
HNF1b allele was performed using TaqMan Assay reagents for
allelic discrimination (Applied Biosystems, Courtaboeuf,
France) with a 7900 Applied Biosystems thermal cycler. All
genotyping was performed in duplo according to quality stand-
ards of the International Federation of Clinical Chemistry and
Laboratory Medicine.
Outcome
The endpoint of this study was PTDM 1 year after trans-
plantation. We chose the 1-year time point because (i) gluco-
corticoids are discontinued in our centre in all patients 3
months after transplantation and (ii) transient post-
transplantation hyperglycaemia is usually resolved 1 year after
transplantation, and does not predict PTDM [40]. PTDM was
defined according to the American Diabetes Association as a
fasting blood glucose>7.0 mmol/L, or a non-fasting blood glu-
cose >11.1 mmol/L [41, 42]. Increased blood glucose levels
were confirmed by repeat testing on a different day. In addition,
patients who started with glucose-lowering drugs after KT were
also considered to have PTDM.
Statistical analysis
Comparisons of the baseline characteristics of patients with
PTDM and patients without PTDM were performed with
Student’s t-tests for continuous variables and Chi-square tests
for categorical variables. Missing data in covariates (<10% of
total) were handled by multiple imputation using the
Multivariate Imputation by Chained Equations package in R
[43]. The number of imputed datasets was based on the average
percentage of missing values [44], and the number of iterations
gradually increased until convergence was achieved. Results are
reported for imputed data, except for the baseline and genetic
data. To examine the association between serum magnesium
levels and whole-blood tacrolimus concentrations, univariate
linear regression was used to calculate the betas, and univariate
logistic regression was used to calculate odds ratios (ORs).
Mixed-design analysis of variance (ANOVA) was used to test
for differences in the repeated measurements (trajectories) of
serum magnesium, whole-blood tacrolimus and eGFR in
patients with and without PTDM. For the regression analyses,
we calculated the area under the curve (AUC) for the trajecto-
ries of serum magnesium and whole-blood tacrolimus. In the
univariate and multivariate logistic regression analyses, we in-
cluded variables based on our hypothesis (serum magnesium
and whole-blood tacrolimus AUC), and those which have pre-
viously been reported as risk factors for PTDM (age and BMI)
[8]. Comparisons of the genetic characteristics of patients with
PTDM and patients without PTDM were made with Chi-
square tests. Univariate and multivariate logistic regressions,
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including dominant and recessive models, were used to exam-
ine the association between HNF1b SNPs and PTDM. A domi-
nant model indicates that either one or two copies of the SNP
allele are needed, whereas a recessive model indicates that two
copies of the SNP allele are needed for the SNP to have an asso-
ciation with PTDM. Data were analysed using SPSS Statistics
for Windows, Version 24.0 (IBM, Armonk, NY, USA) and R
version 3.4.4 (R Foundation for Statistical Computing, Vienna,
Austria). A two-sided P < 0.05 was considered as statistically
significant.
RESULTS
Baseline characteristics
The original clinical trial included 237 patients who received
their first KT from a living donor (Figure 1) [38]. Of these
patients, 50 were excluded because of diabetes mellitus prior to
transplantation, and 20 because of discontinuation of tacroli-
mus, loss-to-follow-up, transplant nephrectomy or death. This
resulted in a total study population of 167 patients of whom 29
(17%) met our definition of PTDM. Despite our conservative
definition of PTDM, this incidence is in agreement with previ-
ous studies [8, 45–47]. The mean age of the study population
was 52 6 14 years and 67 (40%) patients were female. Table 1
shows the comparison of the baseline characteristics of patients
with or without PTDM. Patients with PTDM were significantly
older (606 7 versus 516 15 years, P< 0.001) and had a higher
BMI (28 6 4 versus 26 6 4 kg/m2, P ¼ 0.004). Patients with
PTDM also had a higher blood glucose level prior to KT and 1
year after KT. No differences in whole-blood tacrolimus, serum
magnesium or urine magnesium/creatinine were observed.
None of the patients had hepatitis C [48].
Relationships between tacrolimus, magnesium and
PTDM
We identified significant relationships between whole-blood
tacrolimus concentration, serum magnesium levels and the risk
of hypomagnesaemia at Year 1 (Table 2). Per microgram per li-
tre increase in whole-blood tacrolimus concentration, the se-
rum magnesium level decreased by 0.008 mmol/L (P ¼ 0.003).
In addition, per microgram per litre increase in whole-blood
tacrolimus concentration, the OR for the development of hypo-
magnesaemia increased by 1.28 [95% confidence interval (CI)
1.09–1.50, P¼ 0.003]. Because serummagnesium levels did not
differ between patients with and without PTDM at Year 1
(Table 1), we pursued a repeated measures (trajectory) analysis.
In this analysis, we identified a significant difference between
the serum magnesium trajectory of patients with PTDM com-
pared with patients without PTDM (P ¼ 0.04; Figure 2) . No
significant differences were found between the whole-blood
tacrolimus or eGFR trajectories of patients with and without
PTDM.
Risk factors for PTDM
Possible risk factors for PTDM were analysed in univariate
and multivariate models (Table 3). Based on our hypothesis, we
included the AUC of the whole-blood tacrolimus and serum
magnesium trajectories in the multivariate analysis in addition
to age and BMI. In this multivariate analysis, age (OR ¼ 1.05,
95% CI 1.01–1.10), BMI (OR ¼ 1.11, 95% CI 1.01–1.23) and
the serum magnesium AUC (OR ¼ 0.98, 95% CI 0.96–1.00)
were identified as independent risk factors for PTDM.
Inclusion of the original trial assignment did not change the
results.
FIGURE 1: Flowchart of the study population. Of the 237 eligible patients, 50 patients were excluded because of pre-existing diabetes mellitus.
Of the remaining 187 patients, 20 additional patients were excluded because of discontinuation of tacrolimus, loss-to-follow-up, transplant
nephrectomy or death. This resulted in a total study population of 167 patients, which was further divided into 29 patients with PTDM and
138 participants without PTDM at 1 year after KT.
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SNPs in HNF1b and the risk of PTDM
We analysed the prevalence of three HNF1b SNPs that were
previously implicated in diabetes mellitus in the general popula-
tion (rs752010 G> A, rs4430796 A> G and rs7501939 C> T)
[33]. These SNPs were analysed both in recipients and donors
to analyse if the association between the SNPs and PTDM could
be explained by a renal or non-renal mechanism. When apply-
ing a recessive model, rs752010 G > A was significantly more
common in patients with PTDM compared with patients with-
out PTDM (Table 4). No significant differences were found for
the other two SNPs (Supplementary data, Table S1). In an
unadjusted recessive model, rs752010 G > A in KTRs was also
associated with PTDM (Table 5). This association attenuated
and became borderline significant when correcting for age and
sex. No such associations were identified for the other two
HNF1b SNPs (Supplementary data, Table S2). In addition, we
found no association between HNF1b SNPs of the donor and
the risk of PTDM (data not shown). Finally, we did not find a
significant association between HNF1b SNPs and the risk of
hypomagnesaemia (data not shown).
DISCUSSION
PTDM is a major metabolic complication of KT, but its patho-
genesis is incompletely understood. In this prospective study,
we analysed the role of tacrolimus and serum magnesium on
PTDM.We show that there is a concentration-dependent effect
of the CNI tacrolimus on serum magnesium (Table 2) and that
the serummagnesium AUC in the first year after KT is an inde-
pendent risk factor for the development of PTDM (Table 3).
We also added an exploratory analysis on the role of genetic
variation in the HNF1b gene on the risk of PTDM. This
HNF1b hypothesis was based on reports that (i) patients with
HNF1b mutations develop hypomagnesaemia and diabetes
mellitus [32, 49, 50], (ii) patients with HNF1b mutations are
more prone to develop PTDM [37], (iii) CNIs down-regulate
HNF1b [37] and (iv) SNPs in HNF1b are associated with diabe-
tes mellitus in the general population [33–36, 51, 52]. Although
the univariate analysis showed an association between the
HNF1b SNP rs752010 G > A and PTDM, significance was lost
when adjusting for age and sex (Table 5). Because our study
was not specifically powered to analyse this association, analysis
in a larger cohort is of interest.
Van Laecke et al. [2] were the first to identify associations
between the use of CNIs, serum magnesium and the risk of de-
veloping PTDM. They showed that patients with PTDM had
lower serum magnesium levels and that lower serum magne-
sium levels resulted in a faster development of PTDM. Based on
their analysis, they concluded that the association between CNI
use and PTDM is largely attributable to CNI-induced hypo-
magnesaemia. Similarly, Garg et al. [28] showed that a lower se-
rum magnesium level at 1 month after transplantation
predicted PTDM as well as pre-diabetes. Huang et al. [27] per-
formed the largest retrospective study to date (948 non-diabetic
KTRs) and showed that both a lower post-transplant serum
magnesium level and hypomagnesaemia are independent risk
Table 1. Comparison of baseline characteristics of patients with and without PTDM
Characteristics No PTDM PTDM P-value
(n¼ 138) (n¼ 29)
General characteristics
Age, years 516 15 606 7 <0.001
Female, n (%) 57 (41.3) 10 (34.5) 0.5
BMI, kg/m2 266 4 286 4 0.004
Systolic blood pressure, mmHg 1366 16 1386 13 0.7
Diastolic blood pressure, mmHg 826 10 816 8 0.4
Primary kidney disease
Hypertension 36 (26) 12 (41) 0.1
Polycystic kidney disease 27 (20) 5 (17) 0.8
Glomerular disease 33 (24) 6 (21) 0.7
Other causes 41 (30) 6 (21) 0.3
Laboratory values prior to transplantation
eGFR, mL/min/1.73 m2 106 5 106 4 0.9
Blood glucose, mmol/L 5.1 (4.6–5.7) 5.7 (5.2–6.6) 0.003
Serum magnesium, mmol/L 0.866 0.13 0.886 0.13 0.4
Laboratory values at 1 year
eGFR, mL/min/1.73 m2 486 16 526 17 0.3
Blood glucose, mmol/L 5.5 (4.9–6.2) 6.6 (5.6–8.5) <0.001
Serum magnesium, mmol/L 0.726 0.09 0.696 0.09 0.2
Whole-blood tacrolimus, lg/L 6.46 2.7 6.46 3.0 1.0
Urine magnesium/creatinine, mmol/mmol 0.386 0.23 0.366 0.19 0.8
aData are presented as n (%), mean 6 SD or median (range).
Table 2. Association between whole-blood tacrolimus concentration, serum
magnesium levels and the risk of hypomagnesaemia
Outcome b or OR (95% CI)a P-value
Serum magnesium
(mmol/L)
0.008 (0.014 to 0.0029) 0.003
Hypomagnesaemia
(<0.70 mmol/L)
1.28 (1.09 to 1.50) 0.003
aResults are given per 1 lg/L increase in whole-blood tacrolimus.
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factors for PTDM. Stevens et al. [53] showed that a single-dose
rabbit anti-thymocyte globulin resulted in less PTDM than a
divided-dose, and that this also coincided with less hypomagne-
saemia. In contrast, three retrospective studies (with a study
population ranging from 205 to 589 patients) were unable to
find an association between serum magnesium and PTDM [3,
29, 30]. This discrepancy may be explained by the fact that the
studies by Van Laecke et al. [2], Huang et al., [27] and our study
analysed multiple serum magnesium values rather than focus-
ing on a single value [28]. This suggests that the duration of the
exposure to lower serum magnesium concentrations is impor-
tant for the risk of PTDM. This may also relate to the fact that
serum magnesium is a poor reflection of the intracellular mag-
nesium concentration, which is biologically more relevant [54].
Our research questions primarily focused on the pathogene-
sis of PTDM, but may also be relevant clinically. Although the
association between lower serum magnesium and diabetes mel-
litus has long been recognized [22], the causality of this associa-
tion has remained unclear. Hypomagnesaemia may predispose
to diabetes mellitus, but hyperglycaemia could also lead to in-
creased urinary magnesium excretion and therefore hypomag-
nesaemia. To investigate this directionality, we recently
analysed whether a lower serum magnesium predicts subse-
quent pre-diabetes in the general population [23]. Patients with
pre-diabetes are less likely to develop hyperglycaemia and
therefore urinary magnesium loss. This study showed that
lower serum magnesium was independently associated with a
higher pre-diabetes risk after a median follow-up of 5.7 years
[23]. A clinically more relevant question is whether correction
of magnesium deficiency is able to improve glycaemic control.
Several clinical trials have shown that oral magnesium supple-
mentation can indeed increase serum magnesium and improve
the levels of fasting glucose, insulin and glycated haemoglobin
[55–57]. A recent experimental study extended these effects by
showing that magnesium supplementation also improves mito-
chondrial function, reduces oxidative stress and improves dia-
stolic dysfunction in diabetic mice [58]. One research group
performed two small clinical trials with magnesium supplemen-
tation in hypomagnaesemic KTRs on tacrolimus [59, 60]. The
first trial showed an effect of magnesium supplementation on
fasting glucose but not insulin resistance [60], whereas the sec-
ond trial showed no effects on insulin secretion [59]. Of note, in
both trials magnesium oxide was used, which has a relatively
low bioavailability and high risk of diarrhoea compared with
some of the other magnesium salts (e.g. magnesium chloride,
citrate or lactate) [61, 62].
The association between the HNF1b SNP rs752010 G > A
and PTDM requires further confirmation. Several other SNPs
have been linked to PTDM risk in KTRs, the majority related to
b cell function [63]. One recent study also analysed the associa-
tion between three HNF1b SNPs and PTDM, but did not find
an association [64]. However, HNF1b SNPs have been identi-
fied as risk factors in several studies on the genetic susceptibility
of diabetes mellitus [33–36, 51, 52]. Several of these diabetes
mellitus susceptibility genes also predispose to PTDM, espe-
cially TCF7L2 [65]. The reason for focusing on HNF1b SNPs in
this study was that HNF1b could link CNIs, serum magnesium
and PTDM. In this view, patients with HNF1b SNPs would be
more sensitive to CNI-induced hypomagnesaemia and there-
fore PTDM. However, our data do not support this theory, be-
cause (i) HNF1b SNPs were not associated with
FIGURE 2: Serum magnesium, eGFR and tacrolimus trajectories
during the first year after KT in patients with and without PTDM.
Table 3. Risk factors for the development of PTDM
Univariate analysis Multivariate analysis
Predictor OR (95% CI) P-value OR (95% CI) P-value
Age, per year 1.06 (1.02–1.10) 0.003 1.05 (1.01–1.11) 0.01
BMI, per 1 kg/m2 1.14 (1.04–1.25) 0.006 1.11 (1.01–1.23) 0.03
Tacrolimus AUC 1.00 (0.99–1.00) 0.8 1.00 (0.99–1.00) 0.6
Serum magnesium
AUC
0.98 (0.96–1.00) 0.01 0.98 (0.96–1.00) 0.01
Calculated based on the trajectories in Figure 2.
AUC, area under the curve.
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hypomagnesaemia and (ii) HNF1b SNPs in donors were not as-
sociated with PTDM risk. The HNF1b SNP rs752010 G > A
did show a positive association with PTDM risk in recipients,
but lost significance after correction for age and sex. The value
of this finding remains uncertain in a study that was not specifi-
cally powered to address this association, and it would be of in-
terest to analyse this SNP in a larger cohort of PTDM. If
HNF1b increases the risk of PTDM, this is likely mediated
through an effect on insulin secretion (recipient effect) rather
than an effect on renal magnesium handling (donor effect).
This study has a number of strengths. First, it is the first
study to analyse the relationship between tacrolimus, serum
magnesium and PTDM in a prospective fashion. Serummagne-
sium is not always routinely measured [66], and previous stud-
ies may, therefore, have suffered from confounding by
indication. Secondly, we defined PTDM conservatively as dia-
betes mellitus 1 year after transplantation to exclude transient
forms of PTDM that occur early after transplantation. Thirdly,
we analysed the risk factors of PTDM independent of glucocor-
ticoids because these are discontinued 3 months after KT in our
centre. Glucocorticoids can also cause renal magnesium loss
and contribute to PTDM [26, 67]. Thus, defining PTDM at
Year 1 allowed us tomore specifically address the role of tacroli-
mus on serum magnesium and PTDM risk. Finally, analysing
HNF1b SNPs in both recipient and donor allowed us to address
the question howHNF1bmay contribute to PTDM.
Our study also has a number of limitations. First, this study
was conducted within the framework of a previously conducted
clinical trial [38]. Therefore, the study was not specifically pow-
ered for the research questions of this analysis. However, when
designing the trial, this study was already planned with meas-
urements of serum and urine magnesium at pre-specified time
points. The relatively small sample size did not allow adjust-
ment for multiple covariates and confounders, which may have
limited the external validity of the study. Secondly, because this
was a cohort of KTRs using tacrolimus, we did not have patients
on ciclosporin or a CNI-free regimen as comparators. Thirdly,
the availability of HbA1c or oral glucose tolerance testing may
have resulted in a different incidence of PTDM. Finally, reverse
causality cannot be excluded. For example, patients who devel-
oped PTDM had higher blood glucose prior to KT, as was also
observed by Van Laecke et al. [2]. This could imply that these
patients were more prone to glycosuria and therefore renal
magnesium loss. Conversely, it could also imply that a lower
magnesium after KT contributed to the evolution from pre-dia-
betes to diabetes.
In conclusion, in the first year after KT, a higher tacrolimus
whole-blood concentration is associated with lower serum
magnesium and an increased risk of hypomagnesaemia. Lower
serum magnesium in the first year after KT is an independent
risk factor for PTDM. A separate and novel risk factor for
PTDM may be the HNF1b SNP rs752010 G > A in KTRs,
although this finding requires confirmation in a larger cohort.
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